2nd Quarter - Report

APOTEX CORP. for APOTEX CORP.

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$150,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report Jul 18, 2010 $150,000 Replaced
2nd Quarter - Report (this page) Jul 19, 2010 $150,000 Replaced
2nd Quarter - Amendment Jul 19, 2010 $150,000 Yes

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

S 3606, FY 2011 Agriculture, Rural Development, Food & Drug administration and Related Agencies Act, funding for the FDA's Office of Generic Drugs

Foreign entity interest: ApoSherm Inc., the parent company of Apotex Corp., has direct or indirect ownership interests in companies that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report.

LobbyistCovered position, as disclosed
STEVEN GIULI —

Contacted: HOUSE OF REPRESENTATIVES; Federal Trade Commission (FTC); SENATE

Pharmacy PHA

S. 1315/HR 3777 the Drug Price Competition Act of 2009 S. 369, the Preserve Access to Affordable Generics Act HR 4899 EAH, Supplemental Disaster Relief and Summer Jobs Act of 2010, Chapter 2, Section 4201, Preserve Access to Affordable Generics Act SA 4361 to HR 4213 concerning market blockages caused by pharmaceutical patent settlements HR 759, Food and Drug Administration Globalization Act of 2009 Pharmaceutical waste disposal

Foreign entity interest: ApoSherm Inc., the parent company of Apotex Corp., has direct or indirect ownership interests in companies that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report.

LobbyistCovered position, as disclosed
STEVEN GIULI —

Contacted: Federal Trade Commission (FTC); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 4213 (111th), H.R. 4899 (111th), H.R. 3777 (111th), S. 1315 (111th), H.R. 759 (111th), S. 369 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.